Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Biotechnology

Healthcare
$43.11 +5.87%

+$4.49 today

Market cap
$6.09B
Beta
1.27
P/E (TTM)
-38.4
EPS (TTM)
-$2.11
52W Low $14.30High $82.48

Volume 2.42M

Average 1.82M

ARWR EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR

EBITDA · Q4 FY2026 · quarter ended Sep 2026

EBITDA turns negative

Q4 FY2026 EBITDA was -$405.71M, compared with $64.2M a year earlier. Trailing-twelve-month EBITDA was -$603.58M.

Context

  • EBITDA amounted to 133.9% of revenue in FY2026, up 114.0 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 9 analysts of -$663.07M (-9.9%) for the fiscal year ending Sep 2027, a step up from the -466.2% reported in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$405.71M-174.7% QoQ
Last fiscal yearSep 2026
-$603.59M-466.2% YoY
LTMSep 2026
-$603.58M-466.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-731.9%-147.1%+584.9 pp
1 year-466.2%-9.9%+456.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2026
(603.59M) USD
Year-over-year change
-466.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ARWR compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -466.2% is the lowest of 6, against a peer median of -67.7%.
  • EBITDA amounts to 133.9% of revenue for ARWR, versus a peer median of 196.0%.
ARWR Competitors
EBITDA for ARWR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.15B USD+773.6%—24.0%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€42.88M EUR-67.7%—319.0%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$67.53M USD-3.7%—148.9%
SLNSilence Therapeutics plcLTM Mar 2026-$78.13M USD——8478.5%
WVEWave Life Sciences Ltd.LTM Mar 2026-$174.59M USD-68.4%—243.2%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$473.54M USD-208.3%—49.3%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-$603.58M USD-466.2%—133.9%
Peer median (excluding ARWR) —-67.7%—196.0%

Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue243.23M240.74M3.55M829.45M450.82M
Cost of Revenue10.42M12.49M18.6M01.8M
Gross Profit232.81M228.24M(15.04M)829.45M449.02M
Gross Margin95.7%94.8%-423.7%100.0%99.6%
Research & Development288.5M342.31M489.22M607.16M739.14M
Selling, General & Admin124.43M90.93M96.82M121.92M202.05M
Operating Expenses411.32M433.24M586.04M731.1M1.16B
Depreciation & Amortization10.42M12.49M18.6M23.93M26.62M
EBITDA(162.29M)(175.67M)(561.51M)164.82M(603.59M)
EBITDA Margin-66.7%-73.0%-15812.8%19.9%-133.9%
Operating Income(178.51M)(205M)(601.08M)98.35M(707.17M)
Operating Margin-73.4%-85.2%-16927.1%11.9%-156.9%
Interest Income5.03M15.3M22.72M37.29M57.86M
Interest Expense018.33M32.35M89.36M93.71M
Other Income / Expenses5.8M(1.49M)(11.38M)(46.81M)(16.74M)
Income Before Tax(172.71M)(206.49M)(612.46M)51.53M(723.92M)
Pre-Tax Margin-71.0%-85.8%-17247.5%6.2%-160.6%
Income Tax Expense3.79M2.78M(2.77M)21.42M(6.78M)
Net Income(176.06M)(205.28M)(599.49M)(1.63M)(724.21M)
Net Margin-72.4%-85.3%-16882.4%-0.2%-160.6%
EPS (Basic)(1.67)(1.92)(5.00)(0.01)(5.11)
EPS (Diluted)(1.67)(1.92)(5.00)(0.01)(5.11)
Weighted Avg Shares105.43M106.75M119.78M133.76M141.63M
Weighted Avg Shares (Diluted)105.43M106.75M119.78M133.76M141.63M

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Intrinsic Alpha fair value

Locked

Current Price

$43.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.